

other bloodborne pathogen infections; and (6) develops, implements, and evaluates the effectiveness and impact of interventions to prevent the dissemination of infections endemic in the community (e.g., as tuberculosis and influenza) in healthcare settings.

Health Communications Section (CRM33). (1) With input from DHQP branches, NCID/CDC Centers, Institutes and Offices (CIO's), partners and stakeholders, develops, implements, and evaluates the effectiveness of the DHQP health communications strategic plan to (a) deliver effective messages to target audiences that protect patients, protect healthcare personnel, and promote quality healthcare and (b) inform patients, partners, the public, decision makers, and other constituents about these issues; (2) coordinates provision of DHQP technical support and consultation to partners and constituents on the prevention of healthcare-associated infections/antimicrobial resistance, related adverse events, and medical errors; (3) develops and tests health communication materials in a variety of media, including but not limited to electronic and print; (4) develops and implements a real-time communication network for the delivery of information to intramural and extramural partners and stakeholders; (5) disseminates information to medical, technical, scientific, and lay audiences and news media about healthcare-associated infections/antimicrobial resistance, adverse events, and medical errors; (6) develops, coordinates, and maintains DHQP website; (7) develops and tests material, technologies, and strategies for training programs to prevent and control healthcare-associated infections/antimicrobial resistance, related adverse events, and medical errors; (8) develops and implements national health communication campaigns to promote the prevention and control of healthcare-associated infections/antimicrobial resistance, related adverse events, and medical errors; (9) evaluates the effectiveness of DHQP's health communication strategies to determine the impact and contribution to prevention and control of healthcare-associated infections/antimicrobial resistance, related adverse events, and medical; and (10) oversees DHQP's scientific and editorial clearance process for all print and non-print materials and ensures adherence to and consistency with CDC's scientific and editorial policies and clearance processes.

Healthcare Outcomes Branch (CRM4). (1) Evaluates the impact of healthcare-associated infections/antimicrobial

resistance, related adverse events, and medical errors on healthcare outcomes and costs in order to establish priorities for DHQP intervention programs; (2) improves methods to measure healthcare outcomes, performance, and cost-effectiveness of intervention strategies; (3) improves systems by which health organizations collect, manage, analyze, report, and respond to data on healthcare outcomes, healthcare-associated adverse events, and medical errors; (4) implements and coordinates the National Healthcare Safety Network (NHSN) (a representative sample of healthcare organizations that report data on targeted healthcare-associated adverse events and medical errors) to obtain locally relevant and scientifically valid benchmarks and performance measurements that promote healthcare quality and value; (5) provides national estimates of targeted adverse events and medical errors among selected populations of patients across the spectrum of healthcare delivery sites; and (6) provides national estimates of targeted occupational illnesses and injuries among healthcare workers across the spectrum of healthcare delivery sites.

Quality Research Section (CRM42). (1) Evaluates the impact of healthcare-associated infections/antimicrobial resistance, related adverse events, and medical errors on patient outcomes, healthcare costs, and resource utilization; (2) develops scientifically valid and locally relevant methods of risk adjustment for interpreting and comparing performance measures and healthcare outcomes and costs among targeted populations; (3) develops analytic methods to provide reliable national estimates of the frequency and impact of targeted adverse health events among patients and healthcare personnel; and (4) develops analytic methods to evaluate the relationship among healthcare structure, processes of care, and healthcare outcomes.

Performance Measurement Section (CRM43). (1) with collaborating partners, establishes, maintains, and expands the NHSN to collect, report, monitor, interpret, and disseminate data relevant to healthcare safety, quality, and value; (2) with collaborating partners, develops and validates standard definitions of monitored healthcare events in targeted populations and healthcare settings. These events may include medical device-associated infections/adverse events/errors, drug-associated adverse events/errors, antimicrobial use/misuse, blood product-associated infections/adverse events/errors, procedure-

associated infections/adverse events/errors, laboratory-associated adverse events/errors, vaccine-preventable and antimicrobial-resistant infections, and occupational exposures and infections; (3) develops, implements, and validates protocols for reporting monitored health events in targeted populations and healthcare settings; (4) develops analytic tools to create performance measures and other locally relevant data to enhance quality promotion activities; (5) collaborates with NCID, other CDC CIOs, and other information system partners to ensure that the NHSN and related information systems adhere to relevant standards and emerging architecture for integrated surveillance and information management; (6) coordinates translation of NHSN functional specifications and CDC standards to software developers and maintains ongoing communication with developers as the system evolves; (7) coordinates NHSN data management, data warehousing, and analysis systems; (8) develops information system capacity and transfer protocols to acquire data from various existing databases and sources to provide national estimates of monitored adverse health events among patients and healthcare personnel; (9) develops, updates, and disseminates public use de-identified data sets relevant to healthcare outcomes, infections and other adverse events, and medical errors; (10) investigates novel strategies for data acquisition and electronic reporting of adverse event and relevant data from healthcare organization information systems; and (11) identifies novel strategies for electronic detection, automated reporting, and interpretation of healthcare-associated infections/antimicrobial resistance, related adverse health events, and medical errors.

Dated: January 30, 2001.

Jeffrey P. Koplan,

Director.

[FR Doc. 01-3221 Filed 2-7-01; 8:45 am]

BILLING CODE 4160-18-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N-0051]

Agency Information Collection Activities; Proposed Collection; Comment Request; Adverse Event Pilot Program for Medical Devices and Blood Products

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments concerning a pilot project FDA plans to conduct to obtain adverse event reports from user facilities.

DATES: Submit written or electronic comments on the collection of information by April 9, 2001.

ADDRESSES: Submit electronic comments on the collection of information via the Internet at <http://www.accessdata.fda.gov/scripts/oc/dockets/edockethome.cfm>. Submit written comments on the collection of information to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.

With respect to the following collection of information, FDA invites comments on: (1) Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility;

(2) the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology.

Adverse Event Pilot Program for Medical Devices and Blood Products

Under section 519 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360i), FDA is authorized to require manufacturers to report medical device related deaths, serious injuries, and malfunctions and to require user facilities to report device-related deaths directly to FDA and to manufacturers, and to report serious injuries to the manufacturer. Section 213 of the FDA Modernization Act of 1997 (FDAMA) amended section 519(b) of the act relating to mandatory reporting by user facilities of deaths and serious injuries and serious illnesses associated with the use of medical devices. This amendment required FDA to, by regulation, replace universal user facility reporting with a system that is limited to a " * * * subset of user facilities that constitutes a representative profile of user reports" for device related deaths and serious injuries. This amendment is reflected in section 519(b)(5)(A) of the act.

FDA is the Federal agency charged with the responsibility for ensuring that marketed medical products are safe and effective. To carry out its responsibilities, the agency needs to be informed whenever an adverse event or product problem occurs. Only if FDA is provided with such information will it be able to evaluate the risk, if any, associated with the product and take whatever action is necessary to reduce or eliminate the public's exposure to this risk. Data collected from user facilities about problems with medical devices assist FDA to carry out that mission as it pertains to medical devices. Prior to implementing the regulation to change from universal user facility reporting to reporting by a subset of user facilities, FDA is planning to conduct a pilot program to evaluate various aspects of the new program. The new user facility program that will be comprised of a subset of user facilities is called the Medical Product Surveillance Network (MedSuN). Two FDA Centers, the Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and

Research (CBER) are participating in this project. Data collected from the pilot will aid FDA in fulfilling its mission to monitor the safety and effectiveness of marketed medical devices as they are used in clinical settings and to determine what aspects of the pilot program should be implemented in the national program. The current FDA universal user-facility reporting system remains in place during the piloting of the new program, and will remain until FDA implements the new MedSuN national system by regulation.

An electronic format of the medical device related sections of the mandatory MedWATCH form (form 3500A; OMB Control number 0910-0291) will be accessible to the participating medical device user facilities and the participating blood establishments. The facilities participating in the collection of medical device-related adverse events will use this electronic format in reporting to FDA. The electronic format will include some additional items that are not on the 3500A form. These will be voluntary for participants to complete, such as hospital profile information and several questions related to the use of medical devices.

During this pilot project, FDA is planning to include the electronic collection of voluntary information related to blood products. Currently blood establishments and transfusion centers must investigate and keep records of adverse events regarding blood or blood products arising as a result of blood collection or transfusion (§ 606.170(a) (21 CFR 606.170(a))). In addition, when the event is fatal, FDA must be notified immediately (by phone, fax, express mail, or email) and a written report must be submitted within 7 days of the transfusion (§ 606.170(b)). Deviations in the manufacturing of biological products, including blood and blood components, according to the recently published rule entitled "Biological Products: Reporting of Biological Product Deviations in Manufacturing" (November 7, 2000, 65 FR 66621), must also be reported to FDA when the product is distributed (21 CFR 606.171). The form for these reports is pending OMB approval.

However, these mandatory reports do not include errors related to the use of the product and do not include "near-miss" errors, an important way of analyzing weaknesses in the systems. The "Medical Event Reporting System for Transfusion Medicine" (MERS-TM) has been designed to provide this type of information. For this pilot program, blood transfusion centers and blood establishment centers who currently use

the MERS-TM to track internal events will be recruited to participate. These facilities will be asked to fill in the textual description of the blood-product related adverse event and to transfer the two outcome codes from the MERS-TM concerning problems with blood products to two additional data fields in the electronic format that will be dedicated to collecting this coded information. FDA will compare the information obtained in this reporting system with that obtained under existing mandatory and voluntary systems that are in place for transfusion-related fatalities, product deviations,

and clinical adverse events. FDA will consider the information that is voluntarily reported under this pilot program to design a system that will assist FDA in gathering the most useful data, in the least burdensome manner, for its regulation (including packaging and labeling provisions) of establishments and products used in transfusion medicine.

Participation in this pilot will be voluntary and will initially include 25 hospitals that will respond to the medical device questions. At the same time, an initial nine blood establishments and transfusion services

sites, which currently use the MERS-TM, will be recruited to participate. It is anticipated that during this pilot the number of participants will increase to approximately 250 facilities reporting medical device problems and the number of blood establishments and transfusion-services sites is anticipated to increase to 30. The electronic version will take approximately 45 minutes, or less, to complete. For the blood centers that are participating, the burden of participation will be approximately 15 minutes.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN¹

No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Medical devices: 83	15	1,245	.75	934
Blood transfusions: 10	150	1,500	.25	375

¹ There are no capital costs or operating and maintenance costs associated with this collection of information.

The number of respondents for medical devices was determined by the average number of respondents given that 25 facilities will be enrolled in the first year, up to 100 the second year, and up to 250 the third year. Eighty three is the average of the final complement of 250 facilities. The annual frequency of response is based on FDA's experience with its mandatory and voluntary reporting systems.

The number of respondents for blood transfusions was determined by the average number of respondents given that a total of 30 blood establishments will be enrolled at the end of 3 years. The annual frequency of response was based on the information that the American Red Cross submits about 15 reports per establishment per year. The MERS-TM will yield about a tenfold higher than the American Red Cross rate since it will include close-calls as well as actual adverse events.

Dated: February 2, 2001.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 01-3321 Filed 2-7-01; 8:45 am]

BILLING CODE 4160-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N-0050]

Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Classification/Reclassification; Restricted Devices; Premarket Approval of Medical Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing information collection, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection requirements for premarket approval of medical devices.

DATES: Submit written or electronic comments on the collection of information by April 9, 2001.

ADDRESSES: Submit electronic comments on the collection of information to <http://www.accessdata.fda.gov/scripts/oc/dockets/edockethome.cfm>. Submit

written comments on the collection of information to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1223.

SUPPLEMENTARY INFORMATION:

I. Background

Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. "Collection of information" is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document.